Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPE65 is a critical enzyme in the visual cycle, specifically expressed in the retinal pigment epithelium (RPE) of the eye. It plays an essential role in regenerating 11-cis-retinal, which is necessary for both rod and cone-mediated vision. Mutations in RPE65 are linked to severe inherited retinal dystrophies, and gene therapy approaches have shown promising results in restoring some visual function in patients with LCA2 and related disorders.
Gene therapy to restore functional RPE65 expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal Pigment Epithelium Visual Cycle Enzyme (RPE65).